Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kodiak Sciences stock | 113.56

Own Kodiak Sciences stock in just a few minutes.

Posted

Fact checked

Kodiak Sciences Inc is a biotechnology business based in the US. Kodiak Sciences shares (KOD) are listed on the NASDAQ and all prices are listed in US Dollars. Kodiak Sciences employs 48 staff and has a market cap (total outstanding shares value) of USD$3.5 billion.

How to buy shares in Kodiak Sciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Kodiak Sciences. Find the stock by name or ticker symbol: KOD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kodiak Sciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$113.56, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kodiak Sciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Kodiak Sciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Kodiak Sciences's share price?

Since the stock market crash in March caused by coronavirus, Kodiak Sciences's share price has had significant positive movement.

Its last market close was USD$113.56, which is 48.68% up on its pre-crash value of USD$58.28 and 219.94% up on the lowest point reached during the March crash when the shares fell as low as USD$35.4939.

If you had bought USD$1,000 worth of Kodiak Sciences shares at the start of February 2020, those shares would have been worth USD$737.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,804.47.

Kodiak Sciences share price

Use our graph to track the performance of KOD stocks over time.

Kodiak Sciences shares at a glance

Information last updated 2020-10-20.
Latest market close USD$113.56
52-week range USD$18.52 - USD$81
50-day moving average USD$59.2323
200-day moving average USD$55.0036
Wall St. target price USD$82.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.495

Buy Kodiak Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kodiak Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kodiak Sciences price performance over time

Historical closes compared with the close of $113.56 from 2020-11-16

1 week (2020-11-23) -9.53%
1 month (2020-10-30) 25.05%
3 months (2020-08-28) 122.10%
6 months (2020-05-29) 75.76%
1 year (2019-11-29) 283.65%
2 years (2018-11-30) 1,127.68%
3 years (2017-11-26) N/A
5 years (2015-11-26) N/A

Kodiak Sciences financials

Gross profit TTM USD$0
Return on assets TTM -20.05%
Return on equity TTM -41.34%
Profit margin 0%
Book value $6.972
Market capitalisation USD$3.5 billion

TTM: trailing 12 months

Shorting Kodiak Sciences shares

There are currently 3.7 million Kodiak Sciences shares held short by investors – that's known as Kodiak Sciences's "short interest". This figure is 9.2% up from 3.4 million last month.

There are a few different ways that this level of interest in shorting Kodiak Sciences shares can be evaluated.

Kodiak Sciences's "short interest ratio" (SIR)

Kodiak Sciences's "short interest ratio" (SIR) is the quantity of Kodiak Sciences shares currently shorted divided by the average quantity of Kodiak Sciences shares traded daily (recently around 300289.87034036). Kodiak Sciences's SIR currently stands at 12.34. In other words for every 100,000 Kodiak Sciences shares traded daily on the market, roughly 12340 shares are currently held short.

However Kodiak Sciences's short interest can also be evaluated against the total number of Kodiak Sciences shares, or, against the total number of tradable Kodiak Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kodiak Sciences's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Kodiak Sciences shares in existence, roughly 80 shares are currently held short) or 0.1534% of the tradable shares (for every 100,000 tradable Kodiak Sciences shares, roughly 153 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kodiak Sciences.

Find out more about how you can short Kodiak Sciences stock.

Kodiak Sciences share dividends

We're not expecting Kodiak Sciences to pay a dividend over the next 12 months.

Kodiak Sciences share price volatility

Over the last 12 months, Kodiak Sciences's shares have ranged in value from as little as $18.52 up to $81. A popular way to gauge a stock's volatility is its "beta".

KOD.US volatility(beta: 1.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kodiak Sciences's is 1.4009. This would suggest that Kodiak Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Kodiak Sciences overview

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site